posted on 2021-12-21, 14:52authored byTaylor & FrancisTaylor & Francis, Richard L. Wasserman, Sudhir Gupta, Mark Stein, Christopher J. Rabbat, Werner Engl, Heinz Leibl, Leman Yel
Supplemental Table 1. Participant demographics and baseline characteristics.
Supplemental
Table 2. Annualized rates of infections by IgG route of administration for
subgroup of participants sequentially treated with IVIG, SCIG, and fSCIG and
total population from clinical studies.
Supplemental
Table 3. IgG peak and trough levels by infusion interval.
Supplemental Table 4. Causally related AEs (excluding infections).